Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
Russell-Smith A, Murphy L, Nguyen A, Cao F, Li S, Blauer-Peterson C, Shah R December 11, 2022 ASH 2022 Hematology

Healthcare Resource Utilization and Costs Among Patients With Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin and Blinatumomab During First Salvage in Relapse/Refractory 2

View Presentation View Abstract Plain Language Summary
Poster
de Lima M, Kebriaei P, Lanza F, Cho C, Popradi G, Hemmer MT, Zhang M-J, Zhang F, Shah R, Welch V, Tikka S, Vandendries E, Stelljes M, Marks DI, Saber W December 11, 2022 ASH 2022 Hematology

Veno-Occlusive Disease Risk and Other Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

View Presentation View Abstract Plain Language Summary
Poster
Sharma S, Wang D, Lon H-K, Soltantabar P, Viqueira A, Czibere A, Hickman A, White JL, Elmeliegy M December 12, 2022 ASH 2022 Hematology

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor-T Cell and Bispecific Antibodies for Patients With Relapsed and/or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van Der Velden VHJ, Beverloo HB, Sleight B, Rives S, Diaz-de-Heredia Rubio C, Sirvent FJB, Rubio-San-Simón A, Rialland F, Rizzari C, Bielorai B, Petit A, Bruno B, Øra I, Nilsson A, Engstler G, Rossig C, Brethon B, Locatelli F, Zwaan CM December 12, 2022 ASH 2022 Hematology

Inotuzumab Ozogamicin (InO) Combined With UKALL-R3 Modified Chemotherapy in Pediatric Patients With B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results From the ITCC-059 Phase 1B Trial

View Presentation
Poster
Landgren O, Kazandjian D, O'Connell A, Finn G, Raje N December 12, 2022 ASH 2022 Hematology

MagnetisMM-4: An Open-Label, Phase 1b/2 Umbrella Study of Elranatamab in Combination With Other Anti-Cancer Treatments for Patients With Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Pennesi E, Brivio E, Pelletier KB, Chen Y, Huitema ADR, Jiang Y, Ammerlaan ACJ, Sleight B, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Starý J, Sramkova L, Díaz-de-Heredia C, Rives S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Sirvent FJB, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Garrett M, Zwaan CM December 12, 2022 ASH 2022 Hematology

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) as Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results From the ITCC-059 Phase IA and Phase II Trial

View Presentation
Poster
Li J, Hibma JE, O’Gorman M, McCush F, Kirkovsky L, Chen Y March 24, 2023 ASCPT 2023 Hematology

Characterization of Gemtuzumab Ozogamicin Pharmacokinetics in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Fractionated Dosing Regimen

View Presentation
Poster
Rashid J, Hibma JE, Benner RJ, Bousset P, Vandendries ER, Chen Y March 24, 2023 ASCPT 2023 Hematology

Concentration-QT Modeling Analysis of Gemtuzumab Ozogamicin Following Fractionated Dosing Regimen in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

View Presentation